| Dr Eric J Grigsby, MD | |
|
3434 Villa Ln, Suite 150, Napa, CA 94558-6405 | |
| (707) 252-9666 | |
| (707) 258-2780 |
| Full Name | Dr Eric J Grigsby |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 40 Years |
| Location | 3434 Villa Ln, Napa, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952328494 | NPI | - | NPPES |
| 00G648480 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | G648480 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Queen Of The Valley Medical Center | Napa, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spectrumcare Rehabilitation Medical | 2769450873 | 4 |
News Archive
On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.
The European Medicines Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute myeloid leukemia (AML). The treatment is currently undergoing a Phase I clinical study and a final decision from the European Commission regarding status is expected in a few weeks. Aprea is part of the Karolinska Development portfolio.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
Home videos of infants' movements can be used to help detect a form of autism in a child's first year of life, years earlier than the disorder typically is identified, University of Florida researchers have discovered.
The growing trend of "do-it-yourself" transcranial direct current stimulation (tDCS) poses hidden risks to healthy members of the public who seek to use the technique for cognitive enhancement.
› Verified 1 days ago
| Entity Name | Spectrumcare Rehabilitation Medical |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477578201 PECOS PAC ID: 2769450873 Enrollment ID: O20040916001372 |
News Archive
On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.
The European Medicines Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute myeloid leukemia (AML). The treatment is currently undergoing a Phase I clinical study and a final decision from the European Commission regarding status is expected in a few weeks. Aprea is part of the Karolinska Development portfolio.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
Home videos of infants' movements can be used to help detect a form of autism in a child's first year of life, years earlier than the disorder typically is identified, University of Florida researchers have discovered.
The growing trend of "do-it-yourself" transcranial direct current stimulation (tDCS) poses hidden risks to healthy members of the public who seek to use the technique for cognitive enhancement.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric J Grigsby, MD Po Box 5510, Napa, CA 94581-0510 Ph: (707) 252-9666 | Dr Eric J Grigsby, MD 3434 Villa Ln, Suite 150, Napa, CA 94558-6405 Ph: (707) 252-9666 |
News Archive
On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.
The European Medicines Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute myeloid leukemia (AML). The treatment is currently undergoing a Phase I clinical study and a final decision from the European Commission regarding status is expected in a few weeks. Aprea is part of the Karolinska Development portfolio.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
Home videos of infants' movements can be used to help detect a form of autism in a child's first year of life, years earlier than the disorder typically is identified, University of Florida researchers have discovered.
The growing trend of "do-it-yourself" transcranial direct current stimulation (tDCS) poses hidden risks to healthy members of the public who seek to use the technique for cognitive enhancement.
› Verified 1 days ago